Impax ships authorized generic version of Zomig
HAYWARD, Calif. — Impax Labs has launched an authorized generic drug for migraine headaches under a partnership with AstraZeneca, Impax said.
Impax said its generics division, Global Pharmaceuticals, began shipping authorized generic zolmitriptan tablets and orally disintegrating tablets in the 2.5 mg and 5 mg strengths. The drug is a version of AstraZeneca’s Zomig.
Zomig had sales of about $196 million during the 12-month period that ended in April, according to IMS Health.
Authorized generics are branded drugs marketed under their generic names at a discounted price, usually under a deal between the drug’s manufacturer and a third-party company.
Fred’s declares quarterly cash dividend
MEMPHIS, Tenn. — Fred’s Inc. today announced that its board of directors has declared a quarterly cash dividend of $0.06 per share.
The dividend is payable on June 17, 2013, to shareholders of record as of June 3, 2013.
Fred’s Inc. operates 715 discount general merchandise stores, including 21 franchised Fred’s stores, in the southeastern United States. For more information about the company, visit Fred’s website at www.fredsinc.com.
Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.
RxAlly white paper touts ‘personalized pharmacist care’
LEESBURG, Va. — The prevalence of chronic diseases, increased demand for patient care and failure of many patients to take their medications as prescribed calls for an increased role in the healthcare system for pharmacists, according to a national organization of pharmacies.
RxAlly, which includes more than 22,000 pharmacies nationwide, released a white paper Tuesday titled "Personalized Pharmacist Care: Healing America’s Post-Reform Health Care System." Personalized pharmacist care, the group said, refers to individually tailored, pharmacist-provided clinical and consultative services to improve quality of life for patients and optimize clinical and economic outcomes, combining pharmacists’ expertise with face-to-face interaction between the pharmacist and patient.
"We are excited to release our vision of a nationwide care-delivery model, personalized pharmacist care, that seeks to transform an outdated and ineffective paradigm into one that can benefit all Americans," RxAlly CEO Bruce Roberts said. "The expertise of the pharmacist, which is largely absent elsewhere along the care continuum, is perfectly suited to address the increasing complexities related to medication use, chronic disease prevalence and access to care issues."
The group cited a 2011 U.S. Surgeon General analysis of 298 studies showing that integrating pharmacists into patient care promoted patient engagement and yielded an economic benefit of $10 for every $1 invested. Another study, by RxAlly member Thrifty White, found patients enrolled with medication synchronization with pharmacists were 3.4 to 6.1 times more likely to adhere to medication therapies.